Dr. Reddys News
AllNewsAnnouncementRecos
BSE LIVE
Change:
Volume:
Open:
Prv. Close:
Bid:
()
Offer:
()
NSE LIVE
Change:
Volume:
Open:
Prv. Close:
Bid:
()
Offer:
()
Dr. Reddy's Laboratories Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
| AnnouncementAllotment of shares on exercise of Employee Stock Options
Dr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 116021.72 Crore) operating in Pharmaceuticals sector.
Dr. Reddy's Laboratories Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
| AnnouncementIntimation under Regulation 30 of the SEBI (LODR) Regulations, 2015
Dr. Reddy's Laboratories Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
| AnnouncementDisclosure Under Regulation 30 of SEBI (LODR) Regulations, 2015
Market Wrap: Sensex gains 148 points, Nifty above 24,800 on positive global cues, Fed minutes
| NewsThe Fed minutes confirmed expectations of a rate cut next month, with most policymakers agreeing it would be appropriate if data aligns with forecasts. Market participants are now focused on US initial jobless claims at 6:00 pm IST and Fed Chair Jerome Powell's upcoming remarks at the Jackson Hole Economic Symposium.
The 1QFY25 corporate earnings report revealed both growth and challenges in India’s market. The Nifty50’s earnings rose 4% YoY, aided by companies like HDFC Bank and Tata Motors, despite setbacks from Oil Marketing Companies. The auto sector displayed strong volume growth, while IT services and healthcare sectors met expectations with promising future outlooks.
Nifty achieved a 4% YoY growth in profit after tax (PAT), exceeding Motilal Oswal's 3% estimate, though it's the slowest growth since the pandemic quarter of 2020. Key contributors to this growth were HDFC Bank, Tata Motors, ICICI Bank, Maruti Suzuki, and Tata Consultancy Services (TCS), which together accounted for 127% of the incremental YoY earnings.
Dr. Reddy's Laboratories Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
| AnnouncementDisclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Dr. Reddy's Laboratories Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
| AnnouncementLoss of Share Certificate(s)
Dr. Reddy's Laboratories Announcement under Regulation 30 (LODR)-Newspaper Publication
| AnnouncementCopy of Newspaper Publication
Dr. Reddy's Laboratories Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
| AnnouncementNotice of Postal Ballot
Dr Reddy's Laboratories Ltd has obtained an Establishment Inspection Report from the USFDA for its Duvvada units, now classified as Voluntary Action Indicated. The units underwent an inspection from May 8 to May 17, 2024, which led to a Form 483 with observations. Dr Reddy’s planned to resolve the issues within the given time.
Dr. Reddy's Laboratories Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
| AnnouncementUpdate on the USFDA inspection at the Company''s formulations manufacturing facilities (FTO -7 & FTO-9) in Duvvada, Visakhapatnam
Dr. Reddy's Laboratories Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
| AnnouncementAllotment of equity shares on exercise of Employee Stock Options
Dr. Reddy's Laboratories Announcement under Regulation 30 (LODR)-Newspaper Publication
| AnnouncementCopy of Newspaper Publication
Dr. Reddy's Laboratories Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
| AnnouncementSchedule of Analyst / Institutional Investor Meeting
Dr. Reddy's Laboratories Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
| AnnouncementTranscript of earnings call conducted on July 27, 2024
Dr. Reddy's Laboratories Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
| AnnouncementLicense Agreement with JV Company
Dr. Reddy's Laboratories Announcement under Regulation 30 (LODR)-Acquisition
| AnnouncementDisclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Dr. Reddy's Laboratories Announcement under Regulation 30 (LODR)-Updates on Acquisition
| AnnouncementInvestment in JV Company
Dr. Reddy's Laboratories Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
| AnnouncementLoss of Share Certificate(s)
On Wednesday, the US Federal Reserve maintained its key interest rate at 5.25–5.5% for the eighth consecutive time, as expected, while signaling the possibility of a rate cut in its next meeting in September. From the Nifty stocks, Power Grid Corporation, Coal India, ONGC, HDFC Bank, and Dr Reddy's Laboratories were the top gainers, rising 2-4%. On the other hand, M&M, Tata Steel, Hero MotoCorp, Britannia, and Tata Motors ended with cuts.
Dr. Reddy's Laboratories Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
| AnnouncementScrutinizers Report
Dr. Reddy's Laboratories Shareholder Meeting / Postal Ballot-Outcome of AGM
| AnnouncementOutcome of 40th AGM, Scrutinizers Report and Voting Results.
Dr. Reddy's Laboratories Announcement under Regulation 30 (LODR)-Press Release / Media Release
| AnnouncementPress Release
Bandhan Bank on Friday reported 47% growth in its consolidated net profit at Rs 1,063 crore in the first quarter, compared with Rs 721 crore in the last year period.
Dr. Reddy's Laboratories Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
| AnnouncementAudio Recordings of the Earnings call conducted on July 27, 2024
Additionally the company has also announced that each American Depositary Share (ADS) will still represent 1 equity share. As a result, the number of ADSs held by each American Depositary Receipt holder will increase in proportion to the increase in equity shares.
Dr. Reddy's Lab Q1 Results: While announcing the quarterly numbers, the company's board also approved split of equity shares in the ratio of 1:5, which means that 1 existing share will split into 5. The company said its revenue growth during the quarter was largely driven by growth in global generics revenues in North America as well as India.
Dr. Reddy's Laboratories Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
| AnnouncementInvestment in wholly owned subsidiary company
Dr. Reddy's Laboratories Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
| AnnouncementChanges in authorization for determination and disclosure of materiality of event or information
Dr. Reddy's Laboratories Announcement under Regulation 30 (LODR)-Retirement
| AnnouncementRetirement of Ms. Kalpana Morparia, Independent Director of the Company
Dr. Reddy's Laboratories Board Meeting Outcome for Outcome Of Board Meeting
| AnnouncementOutcome of Board Meeting
Dr. Reddy's Laboratories Unaudited Financial Results For The Quarter Ended June 30, 2024
| AnnouncementUnaudited Financial results for the quarter ended June 30, 2024.
Q1 results today: ICICI Bank, Dr Reddy's among 34 companies to announce earnings on Saturday
| EarningsFinolex Industries, IEC Education, IFB Industries, J&K Bank, Jaiprakash Power, SBFC Finance, Vishal Fabrics, Spandana Sphoorty, Smruthi Organics, NTPC, Genus Power, Gujarat Cotex among others will also declare their June quarter results.
In the preceding March quarter, Dr Reddy's reported a consolidated net profit growth of 36% year-on-year to Rs 1,307 crore, while revenue from operations rose 12% year-on-year to Rs 7,083 crore.
Big movers on D-Street: What should investors do with Dr Reddy's, Suzlon Energy and United Spirits?
| NewsStocks that were in focus include names like Dr Reddy's, which fell 0.79%, Suzlon Energy, which rose 5%, and United Spirits, whose shares declined 4.76% on Wednesday.